If biotech had a Mount Rushmore, whose heads would you chisel in the granite?

The question struck me last week as I was considering the legacy of Vertex Pharma CEO Jeff Leiden upon his retirement. Leiden’s eight-year run at Vertex was a boon for cystic fibrosis patients and shareholders. His tenure cou